Skip to content

Innovative, accessible treatments for the leading causes of death globally

At George Medicines, we believe single-pill fixed dose combinations of existing medicines offer the potential to better manage non-communicable diseases and could have a huge positive social impact by improving lives and reducing the financial burden on patients and health systems.

About Us +

Welcome to
George Medicines

Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.

Our Approach +

About Us

George Medicines is a venture-backed spin-out company from George Health, initially established to commercialise the research of The George Institute for Global Health, one of the world’s leading health research institutes. Learn more about the Institute in its latest Annual Report.

We use the research base and scientific expertise of The George Institute to pursue the late-stage development of our single-pill combination therapies. We also use the commercial expertise of George Health and the infrastructure of George Clinical, the global clinical research organisation, for the formulation and clinical development of our portfolio.

We are backed by leading life sciences venture capital firm Brandon Capital, whose expertise is directed toward supporting its portfolio companies along the path to commercialisation and Brandon BioCatalyst, the largest life sciences investment fund in Australia and New Zealand.


Our Approach

George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. Our differentiated business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.



We are building a strong and diversified proprietary pipeline of innovative single-pill combination therapies, targeting some of the leading causes of death in both developed and developing countries, including hypertension, recurrent intracerebral haemorrhage (stroke), cardiovascular disease and type 2 diabetes.



Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact.


Latest News


Triple combination candidate GMRx4 advances into Phase II clinical development for first-line treatment of type 2 diabetes

GMRx4 is the second candidate to be prioritised in Company’s pipeline of proprietary fixed-dose combination therapies targeting non-communicable diseases George Medicines receives $1.5 million investment from Australia’s national biotechnology incubator CUREator London, UK, 20 July 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading …


In conversation with Professor Neil Poulter on May Measurement Month

Raised blood pressure is the number one cause of preventable death worldwide, and more than half of people who are hypertensive don’t know they have the condition. Over a billion people worldwide have hypertension, with most (two-thirds) living in low- and middle-income countries. Fewer than one in five people with hypertension have the problem under …


Spotlight on Stefan König, Chief Executive Officer

In the first of George Medicines’ Spotlight series of interviews, Chief Executive Officer, Stefan König, discusses his career, what led him to join George Medicines and how the Company is aiming to address the huge unmet need in hypertension treatment Can you tell us about your career before joining George Medicines? What motivated and inspired …


Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to substantially increase efficacy and improve adherence to treatment, while minimising side effects London, UK, January 17 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, …


Chairman’s Statement

“George Medicines is uniquely positioned to change the lives of the more than 2 billion people around the world suffering from non-communicable diseases with our novel single-pill therapies. By targeting underserved populations in established and emerging markets, we are making better medicines for all. And never was it more urgent, as the pandemic has highlighted weaknesses and inequalities in health systems globally”

Professor Stephen MacMahon AO, Chairman, Board of George Medicines

Part of a mission to deliver affordable and scalable treatments and technologies

George Medicines is one of George Health’s four businesses, created to commercialise medicines and technologies that leverage the George Institute’s late-stage clinical research for chronic disease.



Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities


Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities

George Health Technology

Affordable, personalised digital health care for all.

Ellen Medical Devices

The world’s first affordable dialysis system